Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 7

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 7
---
1 under the laws of the State
of Delaware.

Lunai Bioworks Inc. operates
through two subsidiaries, Renovaro Biosciences, Inc. (“Renovaro Biosciences”) and Biosymetrics, Inc. (“Biosymetrics”).

Renovaro Biosciences

Renovaro Biosciences is a biotechnology
company intending, subject to completion of necessary capital raising, to develop advanced allogeneic cell and gene therapies to promote
stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially
to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections.

The strategic benefit of the
allogeneic cell therapy technologies is to potentially allow for the manufacture of large, “off-the-shelf” banks of therapeutic
cells that are readily available on demand by healthcare professionals, to potentially decrease the time between diagnosis and treatment.

In certain treatments (e.g.,
HIV and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.

Renovaro Biosciences may also
seek to explore various approaches for gene therapy design elements to potentially eliminate virus-infected or cancer cells by the modulation
of patient’s immune system. Upon injecting into the patients, these genetically engineered allogeneic cells have little to no risk
of passing those modifications to the patient since they are terminally differentiated with locked functionality to activate the host
immune system. Gene modified allogeneic cells are expected to be rejected naturally once they activate the patient’s immune system
therefore will have a very short survival time.

<div align='center'>S-3</div>

BioSymetrics Overview

BioSymetrics is a biomedical artificial intelligence
company focused on integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence,
to advance biomarker discovery, therapeutic development, and precision medicine. BioSymetrics has developed proprietary machine learning
pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. These insights are designed
to support pharmaceutical research, early disease detection, and personalized treatment strategies.

BioSymetrics collaborates with pharmaceutical companies,
healthcare providers, and academic institutions to co-develop analytical tools and translational research programs. Application areas
of the BioSymetrics platform